News & Articles

Quanterix Director of Medical Affairs discusses the advances revolutionizing Alzheimer’s diagnosis and care

Discover how advances in dried blood spot testing are advancing biomarker analysis and sample collection

Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research

Learn how biomarkers can be used to transform drug approval and patient management in neurodegenerative medicine

Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease

The FDA’s Breakthrough Device designation is granted to products that have the potential to offer a more effective diagnosis of life-threatening diseases

The ultra-sensitive biomarker platform evaluates plasma neurofilament light’s utility across 13 neurodegenerative disorders, Down syndrome and depression

Test deployed on Quanterix' Simoa platform promises 1,000-fold sensitivity improvement

New benchtop design and expanded assay portfolio offers researchers greater access to ultra-sensitive Simoa technology for biomarker detection

Breakthrough research published in PLOS ONE demonstrates quantitative, PCR-free detection of microRNA